TNF superfamily: Costimulation and clinical applications

Cell Biology International

Volumn 33, Issue 4, 2009, Pages 453-465

  Vinay, Dass S ^a   Kwon, Byoung S ^b,c  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c National Cancer Center   (South Korea)

Author keywords

Antigen presenting cells; Costimulation; Immune regulation; T cells; TNF superfamily

Indexed keywords

ANTINEOPLASTIC AGENT; CD134 ANTIGEN; CD137 ANTIGEN; CD137 LIGAND; CD27 ANTIGEN; CD30 ANTIBODY; CD30 ANTIGEN; CD30 LIGAND; CD40 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CD70 ANTIGEN; FAS ANTIGEN; GAMMA INTERFERON; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; GLYCOPROTEIN P 15095; HERPESVIRUS ENTRY MEDIATOR; HERPESVIRUS ENTRY MEDIATOR LIGAND; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN M; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY CD137; MONOCLONAL ANTIBODY CD70; NEUTRALIZING ANTIBODY; OX40 LIGAND; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTHRITIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BREAST CANCER; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL DEATH; COLITIS; CYTOKINE PRODUCTION; DENDRITIC CELL; DIABETES MELLITUS; DISEASE MARKER; EXPERIMENTAL MOUSE; GASTRITIS; GRAFT SURVIVAL; HODGKIN DISEASE; HUMAN; IMMUNOPATHOLOGY; IMMUNOPHARMACOLOGY; IMMUNOREGULATION; IMMUNOSTIMULATION; LEISHMANIASIS; LEUKEMIA; LYMPHOMA; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE SCLEROSIS; NEPHRITIS; NONHODGKIN LYMPHOMA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR REJECTION; VIRUS INFECTION; WALDENSTROEM MACROGLOBULINEMIA;

ANIMALS; B-LYMPHOCYTES; HUMANS; IMMUNITY, CELLULAR; KILLER CELLS, NATURAL; LIGANDS; MACROPHAGES; PROTEIN KINASES; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; TUMOR NECROSIS FACTORS;

EID: 63349100341     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cellbi.2009.02.001     Document Type: Review

References (169)

1. Agematsu K., Nagumo H., Oguchi Y., Nakazawa T., Fukushima K., Yasui K., et al. Generation of plasma cells from peripheral blood memory B cells: synergistic effect of interleukin-10 and CD27/CD70 interaction. Blood 91 (1998) 173-180
2. Aizawa S., Nakano H., Ishida T., Horie R., Nagai M., Ito K., et al. Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NF-κB activation. J Biol Chem 272 (1997) 2042-2045
3. Akiba H., Nakano H., Nishinaka S., Shindo M., Kobata T., Atsuta M., et al. CD27, a member of the necrosis factor receptor superfamily, activates NF-κB and stress-activated protein-kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-κB inducing kinase. J Biol Chem 273 (1998) 13353-13358
4. Akiba H., Atsuta M., Yagita H., and Okumura K.O. Identification of rat OX40 ligand by molecular cloning. Biochem Biophys Res Commun 251 (1998) 131-136
5. Akiba H., Miyahira Y., Atsuta M., Takeda K., Nohara C., Futagawa H., et al. Critical contribution of OX ligand to T helper cell type differentiation in experimental Leishmaniasis. J Exp Med 191 (2000) 375-380
6. Amakawa R., Hakem A., Kundig T.M., Matsuyama T., Simard J.J., Timms E., et al. Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell 84 (1996) 551-562
7. Annunziato F., Romagnani P., Mavilia C., Pizzolo G., Stein H., and Romagnani S. CD30. In: Durum S.K., Hirano T., Vilcek J., and Nicola N.A. (Eds). Cytokine ref (2000), Academic Press, UK 1669-1684
8. Arch R.H., and Thompson C.B. 4-1BB and OX-40 are members of tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor κB. Mol Cell Biol 18 (1998) 558-565
9. Arestides R.S., He H., Westlake R.M., Chen A.I., Sharpe A.H., Perkin D.L., et al. Costimulatory molecule OX40L is critical for both Th1 and Th2 responses in allergic inflammation. Eur J Immunol 32 (2002) 2874-2880
10. Beckmann J., Kurts C., Klebba I., Bayer B., Klempnauer J., and Hoffmann M.W. The role of CD30 in skin and heart allograft rejection in the mouse. Transplant Proc 33 (2001) 140-141
11. Bengtsson A. The role of CD30 in atopic diseases. Allergy 56 (2003) 593-603
12. Berberich I., Shu G.L., and Clark E.A. Cross-linking CD40 on B cells rapidly activates nuclear factor-kappa B. J Immunol 153 (1994) 4357-4366
13. Bertram E.M., Dawicki W., and Watts T.H. Role of T cell costimulation in anti-viral immunity. Semin Immunol 16 (2004) 185-196
14. Bishop D.K. The immunobiology of inductive anti-CD40L therapy in transplantation: allograft acceptance is not dependent upon the deletion of graft-reactive T cells. Am J Transplant 2 (2002) 323-332
15. Bonifaz L., Bonnyay D., Mahnke K., Rivera M., Nussenzweig M.C., and Steinman R.M. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on majorhistocompatibility complex class I products and peripheral CD8- T cell tolerance. J Exp Med 196 (2002) 1627-1638
16. Borst J., Hendriks J., and Xiao Y. CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol 17 (2005) 275-281
17. Bowen M.A., Lee R.K., Miragliotta G., Nam S.Y., and Podack E.R. Structure and expression of murine CD30 and its role in cytokine production. J Immunol 156 (1996) 442-449
18. Bretscher P., and Cohn M. Paralysis and induction involve the recognition of one and two determinants of an antigen, respectively. Science 169 (1970) 1042-1049
19. Calmels B., Paul S., Futin N., Ledoux C., Stoeckel F., and Acres B. Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-L. Cancer Gene Ther 12 (2005) 198-205
20. Cella M., Scheidegger D., Palmer-Lehmann K., Lane P., Lanzavecchia A., and Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 184 (1996) 747-752
21. Choi B.K., Asai T., Vinay D.S., Kim Y.H., and Kwon B.S. 4-1BB-mediated amelioration of experimental autoimmune uveoretinitis is caused by indoleamine 2,3-dioxygenase dependent mechanisms. Cytokine 34 (2006) 233-242
22. Clarke S.R. The critical role of CD40/CD40L in the CD4-dependent generation of CD8+ T cell immunity. J Leukoc Biol 67 (2000) 607-614
23. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity. Nat Rev Immunol 3 (2003) 600-620
24. Cuzzocrea S., Nocentini G., Di Paola R., Mazzon E., Ronchetti S., Genovese T., et al. Glucocorticoidinduced TNF receptor family gene (GITR) knockout mice exhibit a resistance to splanchnic artery occlusion (SAO) shock. J Leukoc Biol 76 (2004) 933-940
25. D'Orlando O., Gri G., Cattaruzi G., Merluzzi B.E., Gattei V., and Pucillo C. Outside inside signaling in CD40-mediated B cell activation. J Biol Regul Homeost Agents 21 (2007) 49-62
26. Del Prete G., Izzolo M.E., and Romagnani S. CD30, Th2 cytokines and HIV infection; a complex and fascinating link. Immunol Today 16 (1995) 76-80
27. Demirci G., and Li X.C. Novel roles of OX40 in the allograft response. Curr Opin Organ Transplant 13 (2008) 26-30
28. Diehl L., den Boer A.T., Schoenberger S.P., van der Voort E.I., Schumacher T.N., Melief C.J., et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 1999 5 (1999) 774-779
29. Diehl L., den Boer A.T., van der Voort E.I., Melief C.J., Offringa R., and Toes R.E. The role of CD40 in peripheral T cell tolerance and immunity. J Mol Med 78 (2000) 363-371
30. Dittmer U., He H., Messer R.J., Schimmer S., Olbrich A.R., Ohlen C., et al. Functional impairment of CD8(+) T cells by regulatory T cells during persistent retroviral infection. Immunity 20 (2004) 293-303
31. Duckett C.S., and Thompson C.B. CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signalling and the control of cell survival. Genes Dev 11 (1997) 2810-2821
32. Duckett C.S., Gedrich R.W., Gilfillan M.C., and Thompson C.B. Induction of nuclear factor κB by the CD30 receptor is mediated by TRAF1 and TRAF2. Mol Cell Biol 17 (1997) 1535-1542
33. Dummer W., Brocker E.B., and Bastian B.C. Elevated serum levels of soluble CD30 are associated with atopic dermatitis, but not with respiratory disorders and allergic contact dermatitis. Br J Dermatol 137 (2003) 185-187
34. Esparza E.M., and Arch R.H. TRAF4 functions as an intermediate of GITR-induced NF-kappaB activation. Cell Mol Life Sci 61 (2004) 3087-3092
35. Falini B., Pileri S., Pizzolo G., Dürkop H., Flenghi L., Stirpe F., et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 85 (1995) 1-14
36. French R.R., Chan H.T., Tutt A.L., and Glennie M.J. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 5 (1999) 548-553
37. French R.R., Taraban V.Y., Crowther G.R., Rowley T.F., Gray J.C., Johnson P.W., et al. Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood 109 (2007) 4810-4815
38. Gedrich R.W., Gilfillan M.C., Duckett C.S., Van Dongen J.L., and Thompson C.B. CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. J Biol Chem 271 (1996) 12852-12858
39. Gilfillan M.C., Noel P.J., Podack E.R., Reiner S.L., and Thompson C.B. Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines. J Immunol 160 (1998) 2180-2187
40. Gotsman I., Sharpe A.H., and Lichtman A.H. T-cell costimulation and coinhibition in atherosclerosis. Circ Res 103 (2008) 1220-1231
41. Gramaglia I., Cooper D., Miner K.T., Kwon B.S., and Croft M. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol 165 (2000) 3043-3050
42. Grewal I.S. CD70 as a therapeutic target in human malignancies. Expert Opin Ther Targets 12 (2008) 341-351
43. Grewal I., and Flavell R.A. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 16 (1998) 111-135
44. Gurney A.L., Marsters S.A., Huang R.M., Pitti R.M., Mark D.T., Baldwin D.T., et al. Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Curr Biol 9 (1999) 215-218
45. Hansen H.P., Kisseleva T., Kobarg J., Horn-Lohrens O., Havsteen B., and Lemke H.A. Zinc metalloproteinase is responsible for the release of CD30 on human tumor cell lines. Int J Cancer 63 5 (1995 Nov 27) 750-756
46. Harrop J.A., McDonnell P.C., Brigham-Burke M., Lyn S.D., Minton J., Tan K.B., et al. Herpes virus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. J Biol Chem 273 (1998) 27548-27556
47. Harrop J.A., Reddy M., Dede K., Brigham-Burke M., Ly S., Tan K.B., et al. Antibodies to TR2 (herpesvirus entry mediator), a new member of the TNF receptor superfamily, block T cell proliferation, expression of activation markers, and production of cytokines. J Immunol 1998 161 (1998) 1766-1794
48. Hendriks J., Loes A., Gravestein L.A., Tesselaar K., van Lier R.A., Schumacher T.N., et al. CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol 1 (2000) 433-440
49. Heshmat N.M., and El-Hadidi E.S. Soluble CD30 serum levels in atopic dermatitis and bronchial asthma and its relationship with disease severity in pediatric age. Pediatric Allergy Immunol 17 (2006) 297-303
50. Ho A.W., Hatjiharissi E., Ciccarelli B.T., Branagan A.R., Hunter Z.R., Leleu X., et al. CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. Blood 112 (2008) 4683-4690
51. Hori T. Role of OX40 in the pathogensis and control of diseases. Int J Hematol 83 (2006) 17-22
52. Iwakoshi N.N., Mordes J.P., Markees T.G., Phillips N.E., Rossini A.A., and Greiner D.L. Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner. J Immunol 164 (2000) 512-521
53. Jacquot S., Kobata T., Iwata S., Morimoto C., and Schlossman S.F. CD154/CD40 and CD70/CD27 interactions have different and sequential functions in T cell-dependent B cell responses: enhancement of plasma cell differentiation by CD27 signaling. J Immunol 159 (1997) 2652-2657
54. Jang I.K., Lee Z.H., Kim Y.J., Kim S.H., and Kwon B.S. Human 4-1BB signals are mediated by TRAF2 and activate nuclear factor-κB (NF-κB). Biophys Biochem Res Commun 242 (1998) 613-620
55. Jenkins M.K. The role of cell division in the induction of clonal anergy. Immunol Today 13 (1992) 69-73
56. Jenkins M.K., and Johnson J.G. Molecules involved in T-cell costimulation. Curr Opin Immunol 5 (1993) 361-367
57. Kaleeba J.A., Offner H., Vandenbark A.A., Lublinski A., and Weinberg A.D. Ox-40 receptor provides a potent co-stimulatory signal capable of inducing encephalitogenicity in myelin-specific CD4+ T cells. Int. Immunol 10 (1999) 453-461
58. Kawabe T., Naka T., Yoshida K., Tanaka T., Fujiwara H., Suematsu S., et al. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1 (1994) 167-178
59. Kawamata S., Hori T., Imura A., Takaori-Kondo A., and Uchiyama T. Activation of Ox-40 signal transduction pathways lead to tumor necrosis factor receptor-associated factor (TRAF)-2 and -5 mediated NF-kappaB activation. J Biol Chem 273 (1998) 5808-5814
60. Kim J.D., Choi B.K., Bae J.S., Lee U.H., Han I.S., Lee H.W., et al. Cloning and characterization of GITR ligand. Genes Immun 4 (2003) 564-569
61. Kobata T., Jacquot S., Kozlowski S., Agematsu K., Schlossman S.F., and Morimoto C. CD27-CD70 interactions regulate B-cell activation by T cells. Proc Natl Acad Sci U S A 92 (1995) 11249-11253
62. Kohm A.P., Williams J.S., and Miller S.D. Cutting edge: ligation of the glucocorticoid-induced TNF receptor enhances autoreactive CD4+ T cell activation and experimental autoimmune encephalomyelitis. J Immunol 172 (2004) 4686-4690
63. Kopf M., Ruedl C., Schmitz N., Gallimore A., Lefrang K., Ecabert B., et al. Ox-40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL responses after virus infection. Immunity 11 (1999) 699-708
64. Kroczek R., and Hamelmann E. T-cell costimulatory molecules: optimal targets for the treatment of allergic airway disease with monoclonal antibodies. J Allergy Clin Immunol 116 (2005) 906-909
65. Kroemer A., Xiao X., Vu M.D., Gao W., Minamimura K., Chen M., et al. OX40 controls functionally different T cell subsets and their resistance to depletion therapy. J Immunol 179 (2007) 5584-5591
66. Kurts C., Carbon F.R., Krummel M.F., Koch K.M., Miller J.F.A.P., and Heath W.R. Signalling through CD30 protects against autoimmune diabetes mediated by CD8T cells. Nature 398 (1999) 341-344
67. Kwon B.S., and Weismann S.M. cDNA sequences of two inducible T-cell genes. Proc Natl Acad Sci U S A 86 (1989) 1963-1967
68. Kwon B.S., Tan K.B., Ni J., Oh K.O., Le Z.H., Kim K.K., et al. A newly identified member of the TNF superfamily with a wide tissue distribution and involvement in lymphocyte activation. J Biol Chem 272 (1997) 14272-14276
69. Kwon B., Yu K.Y., Ni J., Yu G.L., Jang I.K., Kim Y.J., et al. Identification of a novel activation-inducible protein of the tumor necrosis factor receptor superfamily and its ligand. J Biol Chem 274 (1999) 6056-6061
70. Lalmanach-Girard A.C., Chiles T.C., Parker D.C., and Rothstein T.L. T cell-dependent induction of NF-kappa B in B cells. J Exp Med 177 (1993) 1215-1219
71. Lama J., and Ware C.F. Human immunodeficiency virus type 1Nef mediates sustained membrane expression of tumor necrosis factor and the related cytokine LIGHT on activated T cells. J Virol 74 (2000) 9396-9402
72. Laouar A., Haridas V., Vargas D., Zhinan X., Chaplin D., van Lier R.A., et al. CD70+ antigen-presenting cells control the proliferation and differentiation of T cells in the intestinal mucosa. Nat Immunol 6 (2005) 698-706
73. Lee S.Y., Park C.G., and Choi Y. T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors. J Exp Med 183 (1996) 669-674
74. Lee S.Y., Lee S.Y., Kandala G., Liou M.L., Liou H.C., and Choi Y. CD30/TNF receptor-associated factor interaction: NF-κB activation and binding specificity. Proc Natl Acad Sci U S A 93 (1996) 9699-9703
75. Lee W.H., Kim S.H., Lee B.B., Kwon B., Song H., Kwon B.S., et al. TNFRSF14 is involved in atherogenesis by inducing pro-inflammatory cytokines and matrix matalloproteinases. Arterioscler Thromb Vasc Biol 21 (2001) 2004-2010
76. Lee H.S., Shin H.H., Kwon B.S., and Choi H.S. Soluble glucocorticoid-induced tumor necrosis factor receptor (sGITR) increased MMP-9 activity in murine macrophage. J Cell Biochem 88 (2003) 1048-1056
77. Lefrancois L., Altman J.D., Williams K., and Olson S. Soluble antigen and CD40 triggering are sufficient to induce primary and memory cytotoxic T cells. J Immunol 164 (2000) 725-732
78. Lens S.M., Baars P.A., Hooibrink B., Van Oers M.H., and Van Lier R.A. Antigen-presenting cell-derived signals determine expression levels of CD70 on primed T cells. Immunology 90 (1997) 38-45
79. Lens S.M., Tesselaar K., van Oers M.H., and Van Lier R.A. Control of lymphocyte function through CD27-CD70 interactions. Semin Immunol 10 (1998) 491-499
80. Li Z., Mahesh S.P., Kim B.J., Buggage R.R., and Nussenblatt R.B. Expression of glucocorticoid induced TNF receptor family related protein (GITR) on peripheral T cells from normal human donors and patients with non-infectious uveitis. J Autoimmun 21 (2003) 83-92
81. Liu J., Schmidt C.S., Zhao F., Okragly A.J., Glasebrook A., Fox N., et al. LIGHT-deficiency impairs CD8+ T cell expansion, but not effector function. Int Immunol 15 (2003) 861-870
82. Loenen W.A. CD27 and (TNFR) relatives in the immune system: their role in health and disease. Semin Immunol 10 (1998) 417-422
83. Mackey M.F., Barth R.J., and Noelle R.J. The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells. J Leukoc Biol 63 (1998) 418-428
84. Matter M., Odermatt B., Yagita H., Nuoffer J.M., and Ochsenbein A.F. Elimination of chronic viral infection by blocking CD27 signaling. J Exp Med 203 (2006) 2145-2155
85. Mauri D.N., Ebner R., Montgomery R.A., Kochel K.D., Cheung T.C., Yu G.L., et al. Light, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entry mediator. Immunity 8 (1998) 21-30
86. Maxwell J.R., Weinberg A., Prell R.A., and Vella A.T. Danger and OX40 receptor signaling synergizes to enhance memory T cell survival by inhibiting peripheral deletion. J Immunol 164 (2000) 107-112
87. McDonagh C.F., Kim K.M., Turcott E., Brown L.L., Westendorf L., Feist T., et al. Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index. Mol Cancer Ther 7 (2008) 2913-2923
88. McHugh R.S., Whitters M.J., Piccrillo C.A., Young D.A., Shevach E.M., Collins M., et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16 (2002) 311-323
89. Menoret A., Myers L.M., Lee S.J., Mittler R.S., Rossi R.J., and Vella A.T. TGF beta protein processing and activity through TCR triggering of primary Cd8+ T regulatory cells. J Immunol 177 (2006) 6091-6097
90. Michel J., Langstein J., Hofstadter F., and Schwarz H. A soluble form of CD137 (ILA/4-1BB), a member of TNF receptor family, is released by activated lymphocytes and is detectable in sera of patients with rheumatoid arthritis. Eur J Immunol 28 (1998) 290-295
91. Montgomery R.I., Warner M.S., Lum B.J., and Spear P.G. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 87 (1996) 427-436
92. Morel Y., Schiano de Colella J.M., Harrop J., Deen K.C., Holmes S.D., Wattam T.A., et al. Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor. J Immunol 2000 165 (2000) 4397-4404
93. Morel Y., Truneh A., Sweet R.W., Olive D., and Costello R.T. The TNF superfamily members LIGHT and CD154 (CD40 ligand) costimulate induction of dendritic cell maturation and elicit specific CTL activity. J Immunol 2001 167 (2001) 2479-2486
94. Mueller D.L., Jenkins M.K., and Schwartz R.H. Clonal expansion versus clonal inactivation: a costimulatory signaling pathway determines the outcome of T antigen receptor occupancy. Annu Rev Immunol 7 (1989) 445-480
95. Mungara A.K., Brown D.L., Bishop D.K., Wood S.Y., and Cederna P.S. Anti-CD40L monoclonal antibody treatment induces long-term, tissue-specific, immunologic hyporesponsiveness to peripheral nerve allografts. J Reconstr Microsurg 24 (2008) 189-195
96. Munroe M.E., and Bishop G.A. A costimulatory function for T cell CD40. J Immunol 171 (2007) 671-682
97. Muriglan S.J., Ramirez-Montagut T., Alpdogan O., Van Huystee T.W., Eng J.M., Hubbard V.M., et al. GITR activation induces an opposite effect on alloreactive CD4(+) and CD8(+) T cells in graft-versus-host disease. J Exp Med 200 (2004) 149-157
98. Myers L., Croft M., Kwon B.S., Mittler R.S., and Vella A.T. Peptide-specific CD8 regulatory cells use IFN-g to elaborate TGF-β based suppression. J Immunol 174 (2005) 7625-7632
99. Nagumo H., Agematsu K., Shinozaki K., Hokibara S., Ito S., Takamoto M., et al. CD27/CD70 interaction augments IgE secretion by promoting the differentiation of memory B cells into plasma cells. J Immunol 161 (1998) 6496-6502
100. Nathan M.J., Yin D., Eichwald E.J., and Bishop D.K. The immunobiology of inductive anti_CD40L therapy in transplantation: allograft acceptance is not dependent upon the deletion of graft-reactive T cells. Am J Transplant 2 (2002) 323-332
101. Niu L., Strahotin S., Hewes B., Zhang B., Zhang Y., Archer D., et al. Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. J Immunol 178 (2007) 4194-4213
102. Nocentini G., and Riccardi C. GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily. Eur J Immunol 35 (2005) 1016-1022
103. Nocentini G., Giunchi L., Ronchetti S., Krausz L.T., Bartoli A., Moraca R., et al. A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. Proc Natl Acad Sci U S A 94 (1997) 6216-6221
104. Nocentini G., Bartoli A., Ronchetti S., Giunchi L., Cupelli A., Delfino D., et al. Gene structure and chromosomal assignment of mouse GITR, a member of the tumor necrosis factor/nerve growth factor receptor family. DNA Cell Biol 19 (2000) 205-217
105. Nocentini G., Ronchetti S., Bartoli A., Spinicelli S., Delfino D., Brunetti L., et al. Identification of three novel mRNA splice variants of GITR. Cell Death Differ 7 (2000) 408-410
106. Ohshima Y., Tanaka Y., Tozawa H., Takahashi Y., Maliszewski C., and Delespesse G. Expression and function of Ox-40 ligand on human dendritic cells. J Immunol 1997 189 (1997) 3838-3848
107. Okumura M., Hidaka Y., Kuroda S., Takeoka K., Tada H., and Amino N. Increased serum concentration of soluble CD30 in patients with Grave's disease and Hashimotos's thyroiditis. J Clin Endocrinol Metabol 82 (1997) 1757-1760
108. van Oers M.H., Pals S.T., Evers L.M., van der Schoot C.E., Koopman G., Bonfrer J.M., et al. Expression and release of CD27 in human B-cell malignancies. Blood 82 (1993) 3430-3436
109. h1 cell development. Int Immunol 19 (2007) 713-718
110. Pan P.Y., Zang Y., Weber K., Meseck M.L., and Chen S.H. Ox40 ligation enhances primary and cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol Ther 6 (2002) 528-536
111. Paterson D.J., Jefferies D.J., Green J.R., Brandon M.R., Corthesy P., Puklavec M., et al. Antigens of activated rat T lymphocytes including a molecule of ∼50,000 Mr detected only on CD4+ T blasts. Mol Immunol 24 (1987) 1281-1290
112. Paulie S., Ehlin-Henriksson B., Mellstedt H., Koho H., Ben-Aissa H., and Perlmann P. A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes. Cancer Immunol Immunother 20 (1985) 23-28
113. Pizzolo G., Vinante F., Morosato L., Nadali G., Chilosi M., Gandini G., et al. High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS. AIDS 8 (1994) 741-745
114. Pizzolo F., Vinante F., Nadali G., Krampera M., Morosato L., Chilosi M., et al. High serum level of soluble CD30 in acute primary HIV-1 infection. Clin Exp Immunol 108 (1997) 251-253
115. Pollok K.E., Kim Y.J., Zhou Z., Hurtado J.C., Kim K.K., Pickard R.T., et al. The inducible T cell antigen 4-1BB: analysis of expression and function. J Immunol 150 (1993) 771-781
116. Quezada S.A., Jarvinen L.Z., Lind E.F., and Noelle R.J. CD40/CD154 interaction at the interface of tolerance and immunity. Annu Rev Immunol 22 (2004) 307-328
117. Redmond W.L., and Weinberg A.D. Targeting OX40 and OX40L for the treatment of autoimmunity and cancer. Crit Rev Immunol 27 (2007) 415-436
118. Ridge J.P., Di Rosa F., and Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4- T-helper and a T-killer cell. Nature 393 (1998) 474-478
119. Rogers P.R., Song J., Gramaglia I., Killeen N., and Croft M. OX40 promotes Bcl-xL and Bcl-2 expression and essential for long-term survival of CD4+ T cells. Immunity 164 (2001) 445-455
120. Romagnani S., Del Prete G., Maggi E., Chilosi M., Caligaris-Cappio F., and Pizzolo G. CD30 and type 2 T helper (Th2) responses. J Leukoc Biol 57 (1995) 726-730
121. Romagnani P., Annunziato F., Manetti R., Mavilia C., Lasagni L., Manuelli C., et al. High CD30 ligand expression by epithelial cells and Hassal's corpuscles in the medulla of human thymus. Blood 91 9 (1998 May 1) 3323-3332
122. Ronchetti S., Nocentini G., Riccardi C., and Pandolfi P.P. Role of GITR in activation response of T lymphocytes. Blood 100 (2002) 350-352
123. Rooney I.A., Butrovich K.D., Glass A.A., Borborodu S., Bendict C.A., and Whitbeck J.C. The lymphotoxin β receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells. J Biol Chem 275 (2000) 14307-14315
124. Salek-Ardakani S., and Croft M. Regulation of CD4 T cell memory by OX40 (CD134). Vaccine 13 (2006) 872-883
125. Schauer S.L., Wang Z., Sonenshein G.E., and Rothstein T.L. Maintenance of nuclear factor-kappa B/Rel and c-myc expression during CD40 ligand rescue of WEHI 231 early B cells from receptor-mediated apoptosis through modulation of I kappa B proteins. J Immunol 157 (1996) 81-86
126. Scheu S., Alferink J., Pötzel T., Barchet W., Kalinke U., Pfeffer K., et al. Targeted disruption of LIGHT causes defects in costimulatory T cell activation and reveals cooperation with lymphotoxin beta in mesenteric lymph node genesis. J Exp Med 195 (2002) 1613-1624
127. Schnell R., Staak O., Borchmann P., Schwartz C., Matthey B., Hansen H., et al. A phase I study with an anti-CD30 ricin A-chain immunotoxin (ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res 8 (2002) 1779-1786
128. Schonbeck U., and Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 58 (2001) 4-43
129. Schuurhuis D.H., Laban S., Toes R.E., Ricciardi-Castagnoli P., Kleijmeer M.J., van der Voort E.I., et al. Immature dendritic cells acquire CD8+ cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or-dependent stimuli. J Exp Med 192 (2000) 145-150
130. Schwab U., Stein H., Gerdes J., Lemke H., Kirchner H., Schaadt M., et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg ± Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 299 (1982) 65-67
131. Seo S.K., Choi J.H., Kim Y.H., Kang W.J., Park H.Y., Suh J.H., et al. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med 10 (2004) 1088-1094
132. Shaikh R.B., Santee S., Granger S.W., Buitrovich K., Cheung T., Kronenberg M., et al. Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation, and tissue destruction. J Immunol 167 (2000) 6330-6337
133. Shimizu J., Yamazaki S., Takahashi T., Ishida Y., and Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self tolerance. Nat Immunol 3 (2002) 135-142
134. Shin H.H., Lee M.H., Kim S.G., Lee Y.H., Kwon B.S., and Choi H.S. Recombinant glucocorticoid induced tumor necrosis factor receptor (rGITR) induces NOS in murine macrophage. FEBS Lett 514 (2000) 275-280
135. Shin H.H., Kwon B.S., and Choi H.S. Recombinant glucocorticoid induced tumour necrosis factor receptor (rGITR) induced COX-2 activity in murine macrophage Raw 264.7 cells. Cytokine 19 (2002) 187-192
136. Shin H.H., Lee H.W., and Choi H.S. Induction of nitric oxide synthase (NOS) by soluble glucocorticoid induced tumor necrosis factor receptor (sGITR) is modulated by IFN-gamma in murine macrophage. Exp Mol Med 35 (2003) 175-180
137. Smith C.A., Gruss H.J., Davis T., Anderson D., Farrah T., Baker E., et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 73 (1993) 1349-1360
138. So T., and Croft M. Cutting edge: OX40 inhibits TGF-beta- and antigen-driven conversion of naive CD4 T cells into CD25+ Foxp3+ T cells. J Immunol 179 (2007) 1427-1430
139. So T., Lee S.W., and Croft M. Immune regulation and control of regulatory T cells by OX40 and 4-1BB. Cytokine Growth Factor Rev 19 (2008) 253-262
140. Stamenkovic I., Clark E.A., and Seed B. A B lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J 8 (1989) 1403-1410
141. Stuber E., and Strober W. The T cell-B cell interactions via OX40/OX40L is necessary for the T cell-dependent humoral immune response. J Exp Med 183 (1996) 979-989
142. Stuber E., Neurath M., Calderhead D., Fell H.P., and Strober W. Cross-linking of Ox-40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity 2 (1995) 507-521
143. Sugumura K., Ishii N., and Wienberg A.D. The therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol 4 (2004) 420-431
144. Sun Y., Chen H.M., Subudhi S.K., Chen J., Koka R., Chen L., et al. Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med 8 (2002) 1405-1413
145. Suri A., Shimizu J., Katz J.D., Sakaguchi S., Unanue E.R., and Kanagawa O. Regulation of autoimmune diabetes by non-islet-specific Tcells - a role for the glucocorticoid-induced TNF receptor. Eur J Immunol 34 (2004) 447-454
146. Tamada K., Shimozaki K., Chapoval A.I., Zhai Y., Su J., Chen S.F., et al. LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol 164 (2000) 4105-4110
147. Tamada K., Shimozaki K., Chapoval A.I., Zhu G., Sica G., Flies D., et al. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat Med 6 (2000) 283-289
148. Tamada K., Tamura H., Flies D., Fu Y.X., Celis E., Pease L.R., et al. Blockade of LIGHT/LTβ and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. J Clin Invest 2002 109 (2002) 549-557
149. Telford W.G., Nam S.Y., Podack E.R., and Miller R.A. CD30-regulated apoptosis in murine CD8 T cells after cessation of TCR signals. Cell Immunol 182 (1997) 125-136
150. Tesselaar K., Arens R., van Schijndel G.M., Baars P.A., van der Valk M.A., Borst J., et al. Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions. Nat Immunol 4 (2003) 49-54
151. Toes R.E., Schoenberger S.P., van der Voort E.I., Offringa R., and Melief C.J. CD40-CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Semin Immunol 10 (1998) 443-448
152. Toubi E., and Shoenfeld Y. The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity 37 (2004) 457-464
153. Uraushihara K., Kanai T., Ko K., Totsuka T., Makita S., Iiyama R., et al. Regulation of murine inflammatory bowel disease by CD25+ and CD25- CD4+ glucocorticoid-induced TNF receptor family-related gene + regulatory T cells. J Immunol 171 (2003) 708-716
154. Vinay D.S., and Kwon B.S. Genes, transcripts, and proteins of CD137 receptor and ligand. In: Chen L. (Ed). CD137 pathway: immunology and diseases (2006), Springer, New York 1-14
155. Vinay D.S., Cha K., and Kwon B.S. Dual immunoregulatory pathways of 4-1BB signaling. J Mol Med 84 (2006) 726-736
156. Vinay D.S., Kim J.D., and Kwon B.S. Amelioration of mercury-induced autoimmunity by 4-1BB. J Immunol 177 (2006) 5708-5717
157. Wang J., Lo J.C., Foster A., Yu P., Chen H.M., Wang Y., et al. The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. J Clin Invest 108 (2001) 1771-1780
158. Wang Y., Subudhi S.K., Anders R.A., Lo J., Sun Y., Blink S., et al. The role of herpesvirus entry mediator as a negative regulator of T cell-mediated responses. J Clin Invest 113 (2004) 826-835
159. Watts T.H. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23 (2005) 23-68
160. Weinberg A.D. Antibodies to Ox-40 (CD134) can identify and eliminate autoreactive T cells: implications for human auto-immune disease. Mol Med Today 4 (1998) 76-83
161. Weinberg A.D. OX40: targeted immunotherapy implications for tempering autoimmunity and enhancing vaccines. Trends Immunol 23 (2002) 102-109
162. Weinberg A.D., Bourdette D.N., Sullivan T.J., Lemon M., Wallin J.J., Maziarz R., et al. Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Nat Med 2 (1996) 183-189
163. Weinberg A.D., Wegmann K.W., Funutake C., and Whitham R.H. Blocking Ox-40/Ox-40 ligand interaction in vitro and in vivo leads to decreased T-cell function and amelioration of EAE. J Immunol 162 (1999) 1818-1826
164. Weinberg A.D., Rivera M.M., Prell R., Morris A., Ramstad T., Vetto J.T., et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol 164 (2000) 2160-2169
165. Weinberg A.D., Evans D.E., Thahofer C., Shi T., and Prell R.A. The generation of T cell memory: a review describing the molecular and cellular events following OX40 (CD134) engagement. J Leukoc Biol 75 (2004) 962-972
166. Wilcox R.A., Chapoval A.I., Gorski K.S., Otsuji M., Shin T., Flies D.B., et al. Cutting edge: expression of functional CD137 receptor by dendritic cells. J Immunol 168 (2002) 4262-4267
167. Xiao Y., Hendriks J., Langerak P., Jacobs H., and Borst J. CD27 is acquired by primed B cells at the centroblast stage and promotes germinal center formation. J Immunol 172 (2004) 7432-7441
168. Yamada A., Salama A.D., Sho M., Najafian N., Ito T., Forman J.P., et al. CD70 signaling is critical for CD28-independent CD8β T cell-mediated alloimmune responses in vivo. J Immunol 174 (2005) 1357-1364
169. Zhai Y., Guo R., Hsu T.L., Yu G.L., Ni J., Kwon B.S., et al. LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest 102 (1998) 1142-1151